FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL								
	OMB Number:	3235-0287							
	Estimated average burden								
- 1	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Name and Address of Reporting Person* El-Hibri Fuad					Section 30(ii) of the investment Company Act of 1940 Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [EBS]								X Directo	cable) or		erson(s) to Issuer 10% Owner Other (specify	
,	•	` '			3. Date of Earliest Transaction (Month/Day/Year) 11/02/2020								below)			pelow)	
RSBURG	MD	20879		4. If Amendment, Date of Origin						Original Filed (Month/Day/Year)				Form filed by One Reporting Person Form filed by More than One Reporting			
(S:				4:													
1. Title of Security (Instr. 3) 2. Trans Date				ction	2A. Deemed Execution Date,			3. Transaction Code (Instr. Disposed Of (D) (Instr. Di			es Acquirec	I (A) or	5. Amou Securitie Benefici Owned I	5. Amount of Securities Beneficially (Owned Following (ect c irect E 1) (7. Nature of Indirect Beneficial Ownership
			<u> </u>					Code	v	Amount	(A) or (D)	Price	Transac	tion(s)			(Instr. 4)
Stock			11/02	/2020				M ⁽¹⁾		20,000	A	\$26.4	1,14	3,988	D		
Common Stock 11			11/02	′2020				S ⁽¹⁾		20,000	D	\$90.44 ⁽²⁾ 1,1		1,123,988			
ommon Stock		11/03	11/03/2020				M ⁽¹⁾		20,000	A	\$26.4	1,14	3,988	D			
Stock			11/03	/2020				S ⁽¹⁾		20,000	D	\$90.74	4 ⁽³⁾ 1,12	³⁾ 1,123,988		_	
Stock													2,140,463 ⁽⁴⁾ I		1	By intervac, L.L.C.	
Stock													1,524,155 ⁽⁵⁾ I			I	By Biovac, L.L.C.
	-	Гable II -											/ Owned			<u> </u>	
2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution if any	Date,	Transa Code (5. Number 6.		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying		Derivative Security	derivative Securities Beneficially Owned Following Reported	e Ow s For lly Dire or I	m: ect (D) ndirect	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	or					
\$26.45	11/02/2020			M ⁽¹⁾			20,000	(6)		03/09/2022	Common Stock	20,000	\$0.00	59,39	1	D	
\$26.45	11/03/2020			M ⁽¹⁾			20,000	(6)		03/09/2022	Common Stock	20,000	\$0.00	39,39	1	D	
	(FESSIONAL CRESSIONAL	(First) (First) (FESSIONAL DRIVE, SUITABLE SECURITY (Instr. 3) Stock \$2. Conversion or Exercise Price of Date (Month/Day/Year) Price of Derivative Security \$26.45 11/02/2020	(First) (Middle) (FESSIONAL DRIVE, SUITE 400 CRSBURG MD 20879 (State) (Zip) Table I - Note	(First)	CRSBURG MD 20879	(First) (Middle) (First) (Middle) (State) (Zip) Table I - Non-Derivative Security (Instr. 3) Stock 11/02/2020 Stock 11/03/2020 Stock 11/03/2020	Code Non-Derivative Securities (e.g., puts, calls, we security Stock S	Conversion Stock	Emergent BioSolution Security (First) (Middle) Security (Instr. 3) Security (I	Emergent BioSolutions In Emergent BioSolutions In Security (Instr. 3) Security (Instr. 3) Emergent BioSolutions In A. If Amendment, Date of Original File Security (Instr. 3) Execution Date (Month/Day/Year) Execution Date (Instr. 4) Emergent BioSolutions In A. If Amendment, Date of Original File Security (Instr. 3) Execution Date (Instr. 4) Emergent BioSolutions In A. If Amendment, Date of Original File Security (Instr. 3) Emergent BioSolutions In A. If Amendment, Date of Original File Security (Instr. 3) Emergent BioSolutions In A. If Amendment, Date of Original File Security (Instr. 3) Emergent BioSolutions In Info Security (Instr. 3) Emergent BioSolutions In Info Info	Conversion Con	Stock 11/02/2020 M(1) 20,000 D	Security (Instr. 3)	First (Middle First (Middle First (Middle First (Middle First (Middle First (Middle Middle First (Middle Middle M	Emergent BioSolutions Inc. EBS	Final	Final Fina

Explanation of Responses:

- 1. All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- 2. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from \$89.40 to \$91.62. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- 3. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from \$89.97 to \$92.24. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- 4. Intervac, L.L.C. ("Intervac") is the direct owner of 2,140,463 shares of the Issuer's common stock. The Reporting Person serves as the managing member of Intervac and the Reporting Person or his wife serve as the trustee of each of the members of Intervac. The Reporting Person disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
- 5. The Reporting Person, individually, and the Reporting Person and his wife, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C., which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. The Reporting Person disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
- 6. The options vested in three equal installments on March 9, 2016, March 9, 2017 and March 9, 2018.

Remarks:

/s/ Carl A. Valenstein, attorney-11/04/2020 in-fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.